IPO 's IPO on the Shenzhen Stock Exchange's Growth Enterprise Market is terminated, making it the top domestic market share holder in the field of abdominal wall surgery.

On November 19th, Beijing Tianzhu Changyun Medical Technology Co., Ltd. (hereinafter referred to as Tianzhu Changyun) terminated its IPO on the Shenzhen Stock Exchange's ChiNext board. The IPO was terminated because Tianzhu Changyun and its sponsor withdrew the application for listing. According to the "Shenzhen Stock Exchange Stock Issuance and Listing Review Rules (2024 Revision)" Article 62, the Shenzhen Stock Exchange decided to terminate its IPO review. The prospectus shows that Tianzhu Changyun is mainly engaged in the research, development, production, and sales of general surgical medical devices represented by hernia repair products. After more than 20 years of development, the company has three categories of products, including hernia repair products, absorbable anti-adhesion fiber membranes, and sutures. The company operates in the medical device industry, and the concentration of the medical device industry in China is relatively low compared to international medical device industry giants in terms of overall asset size, financial strength, and technology level. The company has achieved the top market share in the domestic market in the field of hernia and abdominal wall surgery and has successfully replaced imported hernia repair patches, establishing a leading industry position and strong market competitiveness. According to the "Chinese Hernia Repair Patch Industry Market Research Report" data, in terms of sales revenue, in 2021, Beijing Medical occupied a market share of 20.64%, ranking first in the market; Medtronic ranked second with a market share of 16.17%; the issuer occupied a market share of 11.29%, ranking third in the industry, higher than Johnson & Johnson, which ranked fourth. In terms of sales volume, Beijing Medical occupied a market share of 12.21%, ranking first; the issuer occupied a market share of 10.43%, ranking second, higher than Medtronic and Johnson & Johnson's market share. The proceeds from this offering, after deducting the issuance expenses, are intended to be used for the following projects: [finances section] In terms of financials, in the years 2020, 2021, and 2022, Tianzhu Changyun achieved revenues of approximately RMB 110 million, RMB 166 million, and RMB 220 million, respectively; and net profits of approximately RMB 34.2694 million, RMB 63.894 million, and RMB 86.0014 million, respectively.